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Streptococcus pneumoniae (SPN; pneumococcus) 
accounts  for  50%  of  bacterial  meningitis  in 
humans. This often devastating infection car­
ries a 30% mortality rate, and up to half of 
survivors  experience  neurological  sequelae   
reflecting a wide spectrum of brain injuries, 
including cortical neuronal necrosis and hippo­
campal  neuronal  apoptosis  (Koedel  et  al., 
2002; van de Beek et al., 2004; Weisfelt et al., 
2006; Weber and Tuomanen, 2007). To cause 
meningitis, bloodborne bacteria must first at­
tach  to  and  penetrate  human  brain  micro­
vascular endothelial cells (hBMECs), which is 
the single­cell layer comprising the majority 
of the blood–brain barrier (BBB; Tuomanen, 
1996;  Kim,  2003).  The  molecular  mecha­
nisms underlying the distinct central nervous 
system (CNS) tropism of SPN are poorly un­
derstood. All SPN clinical isolates express the 
surface­anchored sialidase (neuraminidase) NanA 
(Cámara et al., 1994; Pettigrew et al., 2006) 
that targets sialic acid residues on host cells 
and bacterial flora to promote SPN mucosal 
colonization (Shakhnovich et al., 2002; Tong 
et al., 2002). Here, we use an isogenic SPN 
NanA­deficient  mutant  and  heterologous   
expression of the NanA constructs to probe 
the  contribution  of  this  protein  to  SPN­ 
hBMEC interactions in vitro and BBB pene­
tration in vivo.
RESULTS AND DISCUSSION
SPN NanA mutant and heterologous 
expression of NanA in Lactococcus lactis
NanA is a molecule of 1,035 amino acids and 
107 kD molecular mass containing a C­ter­
minal  LP(X)TG  anchor  motif  for  sortase­ 
mediated  anchoring  to  the  SPN  cell  wall 
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In humans, Streptococcus pneumoniae (SPN) is the leading cause of bacterial meningitis, a 
disease with high attributable mortality and frequent permanent neurological sequelae. The 
molecular mechanisms underlying the central nervous system tropism of SPN are incom-
pletely understood, but include a primary interaction of the pathogen with the blood–brain 
barrier (BBB) endothelium. All SPN strains possess a gene encoding the surface-anchored 
sialidase (neuraminidase) NanA, which cleaves sialic acid on host cells and proteins. Here, 
we use an isogenic SPN NanA-deficient mutant and heterologous expression of the pro-
tein to show that NanA is both necessary and sufficient to promote SPN adherence to 
and invasion of human brain microvascular endothelial cells (hBMECs). NanA-mediated 
hBMEC invasion depends only partially on sialidase activity, whereas the N-terminal 
lectinlike domain of the protein plays a critical role. NanA promotes SPN–BBB interaction 
in a murine infection model, identifying the protein as proximal mediator of CNS entry 
by the pathogen.
© 2009 Uchiyama et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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NanA is necessary and sufficient to promote hBMEC 
adherence and invasion
Studies  of  microbial  interactions  with  the  human  BBB 
have been greatly facilitated by the development of an im­
mortalized hBMEC line retaining the morphological and 
functional  characteristics  of  primary  endothelium  (Kim, 
2006). Adherence and intracellular invasion of hBMEC 
within a membrane­bound vacuole appears to be a common 
phenotypic property of several CNS bacterial pathogens, 
including SPN (Ring et al., 1998), group B Streptococcus 
(Nizet et al., 1997), Escherichia coli K1 (Huang et al., 1995), 
and Haemophilus influenzae (Orihuela et al., 2009). Using 
an in vitro assay, we found the SPN NanA mutant to 
exhibit a >90% decrease in hBMEC adherence and inva­
sion compared with the WT parent strain D39, a defect 
that was corrected upon complementation of the mutant 
with NanA on a plasmid vector (Fig. 1 D; P < 0.001). 
Conversely, heterologous expression of SPN NanA in L. 
lactis conferred a >10­fold increase in the bacterium’s ability 
to adhere to and invade the cultured hBMEC (Fig. 1 E;   
P < 0.001).
A sialidase inhibitor does not fully block NanA-dependent 
hBMEC invasion
To further dissect the roles of SPN NanA and its enzy­
matic  activity  in  mediating  pneumococcal  interactions 
(Lock et al., 1988; Cámara et al., 1994). NanA sialidase ac­
tivity targets at least three linkage classes of substrates: the 
­2,6 and ­2,3 linkages of N­acetyl­neuraminic acid to 
galactose  and  the  ­2,6  linkages  of  N­acetyl­neuraminic 
acid to N­acetyl­galactosamine (Scanlon et al., 1989). To 
investigate the potential contribution of NanA to SPN in­
teractions with the BBB endothelium, we compared the 
well­characterized  serotype  2  strain  clinical  isolate  D39, 
which was originally isolated by Avery in 1916 (Avery   
et al., 1944) and is highly virulent in animal infection models 
(Lanie et al., 2007), to its isogenic mutant NanA, which is 
confirmed  to  possess  a  targeted  nonpolar  mutation  that 
eliminates NanA expression (Winter et al., 1997). Using a 
fluorescent assay, we found the NanA mutant to lack siali­
dase activity present in the WT parent strain D39 (Fig. 1 A). 
For  complementation  and  gain­of­function  analyses,  we 
amplified  the  NanA  gene  from  the  D39  chromosome, 
cloned it into an expression vector to generate the recom­
binant plasmid pNanA, and used this to transform the SPN 
NanA mutant and nonpathogenic Gram­positive bacte­
rium L. lactis, confirming NanA surface expression by flow 
cytometry in the latter (Fig. 1 B). Complementation in trans 
with NanA restored sialidase activity to the SPN NanA 
mutant (Fig. 1 A). Furthermore, compared with the empty 
vector control, pNanA conferred significant sialidase activ­
ity to L. lactis (Fig. 1 C).
Figure 1.  SPN NanA is necessary and sufficient to promote hBMEC invasion and adherence in vitro. (A) Loss of sialidase activity in isogenic SPN 
NanA mutant, which is restored by plasmid complementation. (B) Heterologous expression of NanA on the Lactococcus lactis surface as detected by 
flow cytometry. (C) Gain of neuraminidase activity in L. lactis transformed with plasmid containing SPN NanA. (D) Decreased hBMEC adherence and inva-
sion by NanA mutant compared with WT parent SPN strain, restored by complementation with a NanA-expressing plasmid in trans. (E) Increased hBMEC 
adherence and invasion by L. lactis expressing SPN NanA. Sialidase assay performed three times with similar results; representative experiment shown. 
Adherence and invasion assays performed in triplicate and repeated three times; graphs show cumulative data from all experiments. Error bars represent 
standard deviation, statistical analysis by Student’s t test.JEM VOL. 206, August 31, 2009  1847
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Exogenous sialidase treatment modestly enhances  
NanA-dependent hBMEC invasion
Addition of exogenous sialidase (from Arthrobacter ureafaciens) 
failed to rescue the adherence and invasion defects of the 
SPN NanA mutant, and did not stimulate L. lactis hBMEC 
interactions in the absence of NanA (Fig. 2, A and B). How­
ever, for SPN­ or L. lactis–expressing NanA, exogenous siali­
dase stimulated a modest (20–30%), but statistically significant, 
increase in hBMEC adherence and invasion (Fig. 2, A and B). 
These results indicate that SPN NanA is both necessary and 
sufficient to promote efficient bacterial hBMEC adherence 
and invasion, and suggest that this phenotype is enhanced by, 
but not dependent on, the sialidase activity of the surface­
bound protein.
with hBMEC, we used the broad­spectrum sialidase inhibitor 
2­deoxy­2,3­dehydro­N­acetylneuraminic acid (Neu5Ac2en; 
Holzer et al., 1993). Neu5Ac2en treatment resulted in a 
dose­dependent inhibition of NanA sialidase activity with 
maximal inhibition reaching a plateau between 2.5 and   
10  mM  (Fig.  2  A).  Neu5Ac2en  reduced,  but  did  not   
eliminate,  NanA­dependent  adherence  and  invasion  of 
hBMECs in both the SPN (Fig. 2, B and C) and L. lactis 
(Fig. 2 D) backgrounds. In contrast, the Neu5Ac2en in­
hibitor had no effect on the low­level baseline hBMEC 
interactions present in bacteria lacking NanA (Fig. 2, C 
and D). These findings support a significant contribution 
of NanA to hBMEC invasion that is independent of its 
enzymatic activity.
Figure 2.  Influence of exogenous sialidase or sialidase inhibition on the NanA-mediated hBMEC invasion phenotype. (A) Dose-dependent 
inhibition of the SPN NanA sialidase activity by the inhibitor Neu5Ac2en. (B) Dose-dependent partial inhibition of SPN invasion of hBMEC by Neu5Ac2en. 
(C) Addition of the sialidase inhibitor Neu5Ac2en reduces, but does not eliminate, hBMEC adherence and invasion by WT SPN. (D) Sialidase inhibition re-
duces, but does not eliminate, the ability of NanA to confer an hBMEC adherence and invasion phenotype to L. lactis. (E) Exogenous A. ureafaciens siali-
dase does not rescue hBMEC adherence and invasion defects of the SPN NanA mutant. (F) Exogenous sialidase is not sufficient to promote increased 
hBMEC adherence and invasion by L. lactis lacking NanA. Sialidase assay performed three times with similar results; representative experiment shown. 
Adherence and invasion assays performed in triplicate and repeated three times; graphs show cumulative data from all experiments. Error bars represent 
standard deviation, statistical analysis by Student’s t test.1848 SPN SIALIDASE AND THE BLOOD—BRAIN BARRIER | Uchiyama et al.
Second, SPN NanA belongs to a superfamily of concavalin   
A–like glucanases, including the Vibrio cholerae sialidase (Crennell   
et al., 1994) and the Trypanasoma cruzi trans­sialidase (Buschiazzo 
et al., 2002), which contain a sialic acid cleavage domain and 
a second “lectinlike domain.” Because the sialidase activity of 
NanA is hypothesized to promote SPN colonization by 
modulating carbohydrate moieties on epithelial cell surfaces 
and exposing higher affinity receptors (Tong et al., 2002; 
King et al., 2006), it is conceivable that a NanA lectinlike 
domain, if indeed functional in promoting binding, could 
work together with its enzymatic activity in mediating host 
cell interactions. This laminin G­like domain of NanA is sit­
uated toward the N terminus, and we generated a deletion 
derivative  of  pNanA  lacking  this  domain,  pNanAlect   
(Fig. 3 A). When pNanAlect was used to complement the 
SPN NanA mutant, WT levels of both surface protein   
Relative contributions of NanA enzyme active site and N-
terminal lectinlike domain in pneumococcal hBMEC invasion
Two targeted deletions were constructed in the recombinant 
NanA protein and cloned into expression plasmids (Fig. 3 A). 
These plasmids were then reintroduced by complementation 
into the SPN NanA mutant to determine the consequences 
of each deletion on NanA­mediated hBMEC interactions. 
First, active site residues essential for the sialidase activity of 
SPN NanA have recently been identified (Yesilkaya et al., 
2006), and we deleted a region containing two of these resi­
dues (Glu647 and Arg663) from pNanA to yield the deriva­
tive plasmid, pNanAenz (Fig. 3 A). When pNanAenz was 
used to complement the NanA mutant, surface expression 
of the protein was restored to WT levels as assessed by flow 
cytometry (Fig. 3 B), but, as expected, this expression was 
not associated with detectable sialidase activity (Fig. 3 C). 
Figure 3.  Relative contributions of the NanA enzymatic site and N-terminal “lectinlike” domains to the hBMEC invasion phenotype. 
(A) Scheme for deletion of active site residues and lectinlike domain from recombinant SPN NanA protein; position of protein fragment 318–792 used in 
subsequent studies. (B) Expression of mutant NanA protein constructs similar to that of NanA on the WT SPN surface as detected by flow cytometry using 
a rabbit polyclonal antisera against protein fragment 318–792. (C) Deletion of active site region eliminates NanA-induced sialidase activity in L. lactis, 
whereas deletion of the NanA lectinlike domain has no effect. (D) Targeted elimination of either the NanA enzymatic activity or the N-terminal lectinlike 
domain allows only partial complementation of the defect in hBMEC adherence, invasion, or transcytosis of the NanA mutant versus WT SPN. Sialidase 
and transcytosis assays were performed three times with similar results; representative experiment shown. Adherence and invasion assays were per-
formed in triplicate and repeated at least three times; graphs show cumulative data from all experiments. Error bars represent standard deviation, statisti-
cal analysis by analysis of variance with multiple pairwise comparisons.JEM VOL. 206, August 31, 2009  1849
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the brain endothelium. Consistent with this model, addition 
of rabbit polyclonal antisera raised against the same recom­
binant NanA protein fragment also produced a concentra­
tion­dependent inhibition of SPN hBMEC adherence and 
invasion (Fig. 4 B).
NanA promotes SPN–BBB interaction in vivo
Lastly, we sought to determine whether the marked contri­
bution of SPN NanA to hBMEC adherence and invasion in 
vitro translated to increased capacity of SPN to penetrate the 
BBB in vivo. Our choice of animal model had to exclude the 
confounding contribution of NanA to sustained bacteremia 
because a NanA­deficient SPN mutant was recently found to 
be cleared from the mouse circulation within 24 h of intrave­
nous challenge, whereas the WT parent strain proliferated 
(Manco et al., 2006). To focus specifically on SPN–BBB   
interactions, we developed a short­term (4­h) murine intra­
venous challenge model that incorporated terminal exsangui­
nation by saline perfusion (to eliminate blood contamination), 
allowing calculation of the ratio of SPN CFU in brain versus 
blood at the experimental endpoint. We found that at 4 h, 
the levels of WT D39 and isogenic NanA mutant SPN in 
blood were similar, but the median ratio of brain/blood CFU 
in the WT strain (0.512%) was 16­fold greater than the 
NanA mutant (0.031%; P < 0.01; Fig. 5 A). Histopathologic 
expression (Fig. 3 B) and sialidase enzymatic activity (Fig. 3 C) 
were restored.
The NanA mutant strains complemented with pNanA, 
pNanAEnz or pNanALec were tested in the hBMEC in­
vasion and adherence assays, as well as for their ability to 
transcytose across a polar hBMEC monolayer from the lumi­
nal to basolateral side (Fig. 3 D). In contrast to the full resto­
ration of WT levels of adherence and invasion achieved by 
complementation with a WT NanA expression plasmid   
(Fig. 1 D), the pNanAEnz yielded only partial complemen­
tation of the phenotypes, to 50% WT levels (Fig. 3 D). On 
statistical analysis, these intermediate levels of hBMEC ad­
herence, invasion, and transcytosis were significantly greater 
than those observed for the NanA mutant, although signifi­
cantly less than those observed for the WT parent strain or 
the  mutant  complemented  with  the  intact  NanA  protein 
(Fig. 3 D). Thus, NanA sialidase enzymatic activity makes a 
small, but still demonstrable, contribution to these pneumo­
coccal–hBMEC interactions, which is consistent with the 
modest effects of sialidase inhibition or exogenous sialidase 
treatment (Fig. 2, A–F). In contrast, only a very small increase 
in adherence, invasion, or transcytosis was detected when the 
NanA mutant was complemented with pNanALec (to 
20% WT levels), and this did not achieve statistical signifi­
cance when compared with the same mutant transformed 
with empty vector control. Moreover, the pNanALec­
complemented mutant was significantly less adherent and in­
vasive  than  the  pNanAEnz­complemented  strain  (P  < 
0.001; Fig. 3 D). These data reveal a clear role of the N­ter­
minal lectinlike domain in NanA­mediated pneumococcal 
hBMEC interactions. The dual functionality of pneumococ­
cal NanA in sialic acid cleavage and promotion of host cell 
binding draws analogy to the activities of T. cruzi trans­sialidase, 
a virulence factor that can bind to lymphocytes, neurons, and 
heart endothelial cells to stimulate important host cell activa­
tion and proliferation phenotypes (Saavedra et al., 1999; 
Chuenkova and Pereira, 2000; Gao et al., 2002; Chuenkova 
and PereiraPerrin, 2004).
NanA peptide or anti-NanA antibody inhibits SPN hBMEC 
adherence and invasion
The ability of NanA to promote a level of SPN hBMEC ad­
herence and invasion even in the absence of its sialidase activ­
ity suggested the protein also serves directly as an adhesin/invasin 
moeity for the hBMEC surface or can stimulate an up­regu­
lation of hBMEC processes that promote bacterial uptake in­
dependent of binding. To further probe these possibilities, an 
exogenous NanA protein fragment (amino acids 318–792, 
including key active site residues but lacking sialidase activity) 
was added to the adherence and invasion assays to determine 
if its presence blocked or stimulated SPN­hBMEC interac­
tions. We found a dose­dependent inhibition of SPN adher­
ence and invasion of hBMEC by the recombinant NanA 
protein fragment (Fig. 4 A), which is consistent with a com­
petitive inhibition of cellular receptor(s), suggesting that SPN 
NanA can function in the capacity of an adhesin/invasin for 
Figure 4.  Inhibition of NanA-mediated SPN hBMEC adherence and 
invasion by recombinant protein or antisera. (A) Addition of a recom-
binant NanA protein fragment (amino acids 318–792) produces a dose-
dependent inhibition of SPN hBMEC adherence and invasion. (B) Addition 
of rabbit polyclonal antisera against the same recombinant NanA protein 
fragment produces a concentration-dependent inhibition of SPN hBMEC 
adherence and invasion. Control peptide = bovine serum albumin 5.0 mg/ml;  
control antibody = polyclonal rabbit antihyaluronidase 1:250 final 
dilution. Assays were performed three times with similar results; repre-
sentative assay shown. Error bars represent standard deviation, statistical 
analysis by Student’s t test.1850 SPN SIALIDASE AND THE BLOOD—BRAIN BARRIER | Uchiyama et al.
clinical correlation between the magnitude of free sialic acid 
levels in cerebrospinal fluid during pneumococcal meningitis 
and risk of adverse neurological sequelae including coma has 
been reported (O’Toole et al., 1971).
Loss of two additional SPN surface proteins has been 
previously associated with diminished invasion and trans­
cytosis of cultured hBMEC cells—the fibronectin­binding 
protein PavA and choline­binding protein A (CbpA; Ring 
et al., 1998; Pracht et al., 2005). Operating in the context 
of the low capsule, “transparent” phase variant phenotype 
of SPN, CbpA binds the laminin receptor to promote 
hBMEC adhesion. In concert, CpbA presents SPN cell 
wall phosphorylcholine that attaches to platelet­activating 
factor  receptor  on  the  hMBEC  surface,  promoting  in­
vasion  (Ring  et  al.,  1998).  Although  the  high­capsule, 
“opaque” phenotype of SPN predominates in the blood­
stream (transparent forms are readily phagocytosed), the 
high­frequency switch between the two phase variants is 
sufficient to reveal a contribution of CbpA to BBB pene­
tration in vivo (Orihuela et al., 2004). The studies of NanA 
reported  in  the  present  manuscript  were  all  performed 
with inocula of SPN expressing the opaque phenotype. 
We propose that NanA and CpbA may function synergis­
tically to promote passage of the phase­variant SPN bacte­
rium across the BBB.
analysis and tissue Gram­stain could identify lancet­shaped 
diplococci associated with brain endothelium in sections from 
WT­infected mice; CNS­associated bacteria were scant or 
absent in those animals infected with the isogenic NanA 
mutant (Fig. 5 B).
Role of NanA in SPN–BBB interactions and the development 
of meningitis
We conclude that NanA plays an important role in the SPN 
invasion of BBB endothelial cells and bacterial entry into the 
CNS, the critical first step in the pathogenesis of meningitis. 
The contribution of SPN NanA to hMBEC invasion involves 
an adhesin function, in which the N­terminal lectinlike do­
main plays a critical role, and a small but significant contribu­
tion  of  the  sialidase  activity,  which  may  modify  host  cell 
receptors to reveal higher affinity ligands, as previously hy­
pothesized for NanA in nasal colonization (King et al., 2006). 
After SPN breeches the BBB endothelium, subsequent brain 
injury is more likely the byproduct of different SPN virulence 
determinants  (e.g.,  the  pore­forming  toxin  pneumolysin; 
Braun et al., 2002) or host factors, as previous studies using di­
rect intracerebral installation of SPN in mice or guinea pigs 
identified no differences between WT and NanA mutant in 
meningeal inflammation, hearing loss, or neuronal injury scores 
(Winter et al., 1997; Wellmer et al., 2002). Nevertheless, a 
Figure 5.  NanA contributes to SPN BBB penetration in vivo. (A) Comparison of bacterial counts (CFU) recovered from the blood and brain of mice 
4 h after intravenous challenge with 5 × 107 CFU of WT SPN strain D39 or its isogenic NanA mutant. Results represent a single large experiment with  
n = 8 per group; all data shown. Because of the technically challenging complete saline perfusion before brain harvesting, individual mouse infections 
were initiated at staggered timed, with validation of bacterial inocula throughout by CFU counts. Although blood CFU recovered at 4 h did not differ be-
tween the two groups (P = 0.37), the ratio of brain CFU/blood CFU in individual mice was significantly higher in mice infected with the WT SPN strain 
than the NanA mutant (P < 0.01). Statistics by Student’s t test; red line shows median. A repeat experiment performed without saline perfusion and 
using a 6-h time point yielded similar results (Fig. S1). (B) Representative histopathological examination (100× oil immersion) of brain from WT SPN- 
infected mice showed Gram-positive cocci in association with brain microvascular endothelium or within the brain parenchyma (arrows); such findings 
were extremely rare or absent in animals infected with the NanA mutant. Bar, 15 µM.JEM VOL. 206, August 31, 2009  1851
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360 nm, emission 460 nm) was recorded every 15 min from time 0 to 1 h, 
with reported values corrected for the reaction blank containing phosphate 
citrate buffer alone.
hBMEC assays. Immortalized hBMEC line hBMEC, a product of SV­40 
large T antigen transformation maintaining the morphological and func­
tional characteristics of primary endothelium, was obtained from K.S. Kim 
(Johns Hopkins University, Baltimore, MD). hBMECs were maintained in 
RPMI 1640 medium (Life Tech Technologies, Inc.) supplemented with 
10% FBS, 10% NuSerum (BD), and 1% MEM nonessential amino acids, and 
were incubated at 37°C in 5% CO2. Bacterial adherence and invasion assays 
were  performed  essentially  as  previously  described  (Doran  et  al.,  2005) 
within 24 h of established confluence (105 cells/well) at multiplicity of 
infection = 10 bacteria/cell and duration 30 min (adherence assays) or 2 h 
(invasion assays). For a transcytosis assay, hBMEC were grown to conflu­
ence on collagen­coated 3 µM pore size Transwell plates (Corning­Costar); 
5 × 105 CFU of log­phase SPNs were added to the upper (luminal) cham­
ber, and CFU reaching the lower chamber enumerated at the 4­h time 
point. For inhibition studies, a recombinant NanA protein fragment (resi­
dues 318–792) at 2.5 or 5.0 µg/well or anti­NanA rabbit polyclonal antisera 
at 1:250 or 1:500 final dilution were added to the adherence and invasion 
assays as indicated; controls for these experiments were bovine serum albu­
min (5.0 µg/well) and rabbit polyclonal antihyaluronidase antisera (1:250 
dilution), respectively.
Murine model of SPN brain endothelial cell invasion. 8–10 wk old 
male BALB/c mice were injected intravenously with 5 × 107 CFU of SPN 
D39 or its isogenic D39NanA mutant. 4 h after injection, blood was col­
lected and serial dilutions plated to enumerate bacterial CFU in the circula­
tion. Mice were then deeply anesthesized using an intraperitoneal injection 
of  ketamine  (100  mg/kg)  and  xylazine  (10  mg/kg).  Their  chests  were 
opened, and blood was cleared by inserting a 23­gauge needle into the left 
ventricle, perfusing with sterile PBS for 7 min using a peristaltic perfusion 
pump (P­1; GE Healthcare), and allowing fluid to exit through the right 
atrium. After perfusion, brains were removed and the hemispheres were 
separated. One half of the brain was homogenized in PBS, diluted, and 
plated on THY agar plates to enumerate bacteria tightly adherent to the 
BBB; the other half was fixed in PBS + 4% PFA for histopathological analysis. 
A repeat mouse challenge experiment was performed as above, omitting the 
perfusion step, and using a 6­h rather than 4­h experimental endpoint.
Assurances. All animal experiments were approved by the University of 
California, San Diego (UCSD) Committee on the Use and Care of Animals 
and performed using accepted veterinary standards. The UCSD Biosafety 
Committee approved all protocols for bacteriologic experiments.
Online supplemental material. Fig. S1 is a repeat intravenous mouse 
challenge of WT SPN versus isogenic NanA mutant to quantify bac­
terial entry into the brain compared with bacterial levels in the blood. 
This experiment represents a replicate of the study shown in Fig. 5, but 
omitting the saline perfusion step and using 6 h rather than 4 h end­
point. Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20090386/DC1.
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The conservation of NanA expression in all clinical iso­
lates of SPN prompted interest in the recombinant protein 
as a universal vaccine antigen against this leading pathogen 
(Tong et al., 2005; Yesilkaya et al., 2006), as current conju­
gate polysaccharide vaccines only target a subset of the most 
common SPN serotypes. Our identification of NanA func­
tion  in  hBMEC  adherence  and  invasion  suggests  such   
immunization strategies could have an added benefit in re­
ducing the risk of meningitis as a secondary complication of 
invasive infection.
MATERIALS AND METHODS
Bacterial strains and preparation of inocula. SPN serotype 2 strain D39 
(NCTC 7466) and its isogenic D39NanA mutant were used for these ex­
periments. D39NanA was constructed by nonpolar insertion­duplication 
mutagenesis of the nanA gene, as previously described (Winter et al., 1997). 
SPN cultures were grown in Todd­Hewitt broth (THB) + 2% yeast extract 
(THY media). For complementation studies, the SPN NanA mutant was 
transformed with empty vector control (pDC123), pNanA, or the deletion 
plasmids pNanAlect and pNanAenz, and grown in THY + 2 µg/ml 
chloramphenicol. L. lactis strain NZ9000 transformed with pENanA or empty 
vector control (pDCerm) were grown in THB + erythromycin (5 µg/ml). 
Surface expression of proteins was confirmed using a rabbit polyclonal anti­
sera against NanA protein fragment (318–792), a fluorescent secondary anti­
body, and flow cytometry. After overnight incubation at 37°C, with 5% 
CO2, bacteria were reinoculated into fresh media, grown to mid­logarithmic 
growth phase (OD600nm = 0.4), centrifuged at 4,000 rpm for 5 min, washed 
once with PBS, and then resuspended in the appropriate buffer for use in the 
assays described inthe following paragraphs.
Generation of NanA expression plasmids. The NanA gene was am­
plified  by  PCR  from  the  D39  chromosome  using  primers  NanAUpF 
(5­GATTGGAGAAAGGAGAGGGG­3) and NanADownR (5­CGT­
ATCAGCCTGAATGTCATC­3), and the resulting amplicon direction­
ally cloned into plasmid pDCerm to yield the expression plasmid pENanA   
for gain­of­function studies in L. lactis. The amplicon was also subcloned 
into pDC123, which is identical to pDCerm but bearing a chlorampheni­
col instead of erythromycin resistance marker, for complementation stud­
ies in the SPN NanA mutant. Critical active site residues of NanA were 
eliminated from pENanA by inverse PCR using primers NanAenzUp   
(5­TGTATTTTGCGCACGTCTATTGTTC­3) and NanAenzDown 
(5­GGTTGACTGGAGATCTTCAGGTTG­3). Blunt end ligation of the 
amplicon deleted residues 645–662, including 2 amino acids critical for 
sialidase activity, and the modified, enzyme­dead NanA was subcloned into 
vector pDC123 to produce pNanAenz, an expression plasmid for comple­
mentation analysis using the NanA mutant. To eliminate the N­terminal 
lectinlike domain of NanA, a similar process of inverse PCR followed by 
blunt end ligation was performed on pENanA using the primers NanAlecUp 
(5­GGTTGAGCTCTCCCCCGAAAG­3) and NanAlecDown (5­ATG­
CCAGATGTAACGCATGTGCA­3). Subcloning of the modified peptide 
into pDC123 yielded pNanAlec, an expression/complementation plasmid 
containing NanA with a deletion of residues 74–229.
Sialidase activity assay. A quantitative assay using 4­Methylumbelliferyl­
N­acetyl­­d­neuraminic acid sodium salt hydrate (4­MU; Fluka USA) was 
used to assay sialidase activity. SPN (WT D39 and isogenic NanA mutant) 
and L. lactis–expressing NanA constructs were centrifuged, washed once, re­
suspended in 100 µl 0.1M phosphate citrate buffer (pH 6.5) to 109 CFU/ml. 
Bacterial suspensions were sonicated (Sonic Dismembrator 550; Thermo 
Fisher Scientific) on ice for 5 s, followed by 15­s rest intervals × 5 cycles. 
Sample aliquots of 50 µl were added to individuals wells of a 96­well mi­
crotiter plate and mixed with 50 µl of 4­MU diluted to 0.35% in phosphate 
citrate buffer. The plate was incubated at 37°C and fluorescence (excitation 1852 SPN SIALIDASE AND THE BLOOD—BRAIN BARRIER | Uchiyama et al.
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